Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory

被引:62
作者
Cubillo, A. [1 ]
Smith, A. B. [1 ]
Barrett, N. [1 ]
Giampietro, V. [2 ]
Brammer, M. [2 ]
Simmons, A. [2 ,3 ,4 ,5 ]
Rubia, K. [1 ]
机构
[1] Kings Coll London, Dept Child & Adolescent Psychiat, Inst Psychiat, London WC2R 2LS, England
[2] Kings Coll London, Dept Neuroimaging, Inst Psychiat, London WC2R 2LS, England
[3] Kings Coll London, Ctr Neurodegenerat Res, Inst Psychiat, London WC2R 2LS, England
[4] Kings Coll London, NIHR Biomed Res Ctr Mental Hlth, South London & Maudsley NHS Trust, London WC2R 2LS, England
[5] Kings Coll London, Inst Psychiat, London WC2R 2LS, England
关键词
Atomoxetine; attention deficit hyperactivity disorder; functional magnetic resonance imaging; methylphenidate; n-back; working memory; FUNCTIONAL MAGNETIC-RESONANCE; GENERIC BRAIN ACTIVATION; DEFICIT/HYPERACTIVITY DISORDER; STIMULANT-MEDICATION; EXECUTIVE FUNCTIONS; ADHD; CHILDREN; METAANALYSIS; INHIBITION; DOPAMINE;
D O I
10.1017/S0033291713000676
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background The catecholamine reuptake inhibitors methylphenidate (MPH) and atomoxetine (ATX) are the most common treatments for attention deficit hyperactivity disorder (ADHD). This study compares the neurofunctional modulation and normalization effects of acute doses of MPH and ATX within medication-naive ADHD boys during working memory (WM). Method A total of 20 medication-naive ADHD boys underwent functional magnetic resonance imaging during a parametric WM n-back task three times, under a single clinical dose of either MPH, ATX or placebo in a randomized, double-blind, placebo-controlled, cross-over design. To test for normalization effects, brain activations in ADHD under each drug condition were compared with that of 20 age-matched healthy control boys. Results Relative to healthy boys, ADHD boys under placebo showed impaired performance only under high WM load together with significant underactivation in the bilateral dorsolateral prefrontal cortex (DLPFC). Both drugs normalized the performance deficits relative to controls. ATX significantly enhanced right DLPFC activation relative to MPH within patients, and significantly normalized its underactivation relative to controls. MPH, by contrast, both relative to placebo and ATX, as well as relative to controls, upregulated the left inferior frontal cortex (IFC), but only during 2-back. Both drugs enhanced fronto-temporo-striatal activation in ADHD relative to control boys and deactivated the default-mode network, which were negatively associated with the reduced DLPFC activation and performance deficits, suggesting compensation effects. Conclusions The study shows both shared and drug-specific effects. ATX upregulated and normalized right DLPFC underactivation, while MPH upregulated left IFC activation, suggesting drug-specific laterality effects on prefrontal regions mediating WM.
引用
收藏
页码:633 / 646
页数:14
相关论文
共 84 条
[1]  
[Anonymous], 2008, ATT DEF HYP DIS DIAG
[2]  
APA A.P. A., 2000, Diagnostic and statistical manual of mental disorders: DSM-IV, V4th
[3]   The fractionation of working memory [J].
Baddeley, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) :13468-13472
[4]  
Brain Image Analysis Unit, 2011, XBAM
[5]   Generic brain activation mapping in functional magnetic resonance imaging: A nonparametric approach [J].
Brammer, MJ ;
Bullmore, ET ;
Simmons, A ;
Williams, SCR ;
Grasby, PM ;
Howard, RJ ;
Woodruff, PWR ;
RabeHesketh, S .
MAGNETIC RESONANCE IMAGING, 1997, 15 (07) :763-770
[6]   Intellectual functioning in adults with ADHD: A meta-analytic examination of full scale IQ differences between adults with and without ADHD [J].
Bridgett, DJ ;
Walker, ME .
PSYCHOLOGICAL ASSESSMENT, 2006, 18 (01) :1-14
[7]  
Bullmore ET, 1999, HUM BRAIN MAPP, V7, P38, DOI 10.1002/(SICI)1097-0193(1999)7:1<38::AID-HBM4>3.3.CO
[8]  
2-H
[9]  
Bullmore ET, 2001, HUM BRAIN MAPP, V12, P61, DOI 10.1002/1097-0193(200102)12:2<61::AID-HBM1004>3.0.CO
[10]  
2-W